Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
Genomic analysis has played a significant role in the identification of driver mutations that are linked to disease progression and response to drug treatment in ovarian cancer. A prominent example is the stratification of epithelial ovarian cancer (EOC) patients with homologous recombination defici...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1503107/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556909738426368 |
|---|---|
| author | Trudy J. Philips Britt K. Erickson Stefani N. Thomas |
| author_facet | Trudy J. Philips Britt K. Erickson Stefani N. Thomas |
| author_sort | Trudy J. Philips |
| collection | DOAJ |
| description | Genomic analysis has played a significant role in the identification of driver mutations that are linked to disease progression and response to drug treatment in ovarian cancer. A prominent example is the stratification of epithelial ovarian cancer (EOC) patients with homologous recombination deficiency (HRD) characterized by mutations in DNA damage repair genes such as BRCA1/2 for treatment with PARP inhibitors. However, recent studies have shown that some epithelial ovarian tumors respond to PARP inhibitors irrespective of their HRD or BRCA mutation status. An exclusive focus on the genome overlooks the significant insight that can be gained from other biological analytes, including proteins, which carry out cellular functions. Proteogenomics is the integration of genomics, transcriptomics, epigenomics and proteomics data. This review paper provides novel insight into the role of proteogenomics as an analytical approach to identify predictive biomarkers of drug treatment response in epithelial ovarian cancer. Proteogenomic analysis can facilitate the identification of predictive biomarkers of drug treatment response, consequently greatly improving the stratification of patients with EOC for treatment towards a goal of personalized medicine. |
| format | Article |
| id | doaj-art-fc723d425bff4950951d8278a2cde9f8 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-fc723d425bff4950951d8278a2cde9f82025-01-07T05:23:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15031071503107Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancerTrudy J. Philips0Britt K. Erickson1Stefani N. Thomas2Molecular Pharmacology and Therapeutics Graduate Program, University of Minnesota School of Medicine, Minneapolis, MN, United StatesDepartment of Obstetrics, Gynecology and Women’s Health, University of Minnesota School of Medicine, Minneapolis, MN, United StatesDepartment of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, MN, United StatesGenomic analysis has played a significant role in the identification of driver mutations that are linked to disease progression and response to drug treatment in ovarian cancer. A prominent example is the stratification of epithelial ovarian cancer (EOC) patients with homologous recombination deficiency (HRD) characterized by mutations in DNA damage repair genes such as BRCA1/2 for treatment with PARP inhibitors. However, recent studies have shown that some epithelial ovarian tumors respond to PARP inhibitors irrespective of their HRD or BRCA mutation status. An exclusive focus on the genome overlooks the significant insight that can be gained from other biological analytes, including proteins, which carry out cellular functions. Proteogenomics is the integration of genomics, transcriptomics, epigenomics and proteomics data. This review paper provides novel insight into the role of proteogenomics as an analytical approach to identify predictive biomarkers of drug treatment response in epithelial ovarian cancer. Proteogenomic analysis can facilitate the identification of predictive biomarkers of drug treatment response, consequently greatly improving the stratification of patients with EOC for treatment towards a goal of personalized medicine.https://www.frontiersin.org/articles/10.3389/fonc.2024.1503107/fullovarian cancerPARP inhibitorproteogenomicsimmunotherapybiomarkersantibody drug conjugate (ADC) |
| spellingShingle | Trudy J. Philips Britt K. Erickson Stefani N. Thomas Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer Frontiers in Oncology ovarian cancer PARP inhibitor proteogenomics immunotherapy biomarkers antibody drug conjugate (ADC) |
| title | Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer |
| title_full | Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer |
| title_fullStr | Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer |
| title_full_unstemmed | Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer |
| title_short | Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer |
| title_sort | opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer |
| topic | ovarian cancer PARP inhibitor proteogenomics immunotherapy biomarkers antibody drug conjugate (ADC) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1503107/full |
| work_keys_str_mv | AT trudyjphilips opportunitiesforpredictiveproteogenomicbiomarkersofdrugtreatmentsensitivityinepithelialovariancancer AT brittkerickson opportunitiesforpredictiveproteogenomicbiomarkersofdrugtreatmentsensitivityinepithelialovariancancer AT stefaninthomas opportunitiesforpredictiveproteogenomicbiomarkersofdrugtreatmentsensitivityinepithelialovariancancer |